{
 "drug": "Idelalisib Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "04/07/2026",
 "dayN": 140,
 "cat": "Oncology",
 "companies": [
  "Gilead Sciences, Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "04/07/2026",
   "update_type": "New",
   "initial_posting_date": "04/07/2026",
   "package_ndc": "61958-1701-1",
   "generic_name": "Idelalisib Tablet",
   "contact_info": "800-445-3235",
   "related_info": "Discontinuation in the manufacturing of the drug",
   "openfda": {
    "application_number": [
     "NDA205858"
    ],
    "brand_name": [
     "ZYDELIG"
    ],
    "generic_name": [
     "IDELALISIB"
    ],
    "manufacturer_name": [
     "Gilead Sciences, Inc."
    ],
    "product_ndc": [
     "61958-1701",
     "61958-1702"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "IDELALISIB"
    ],
    "rxcui": [
     "1544465",
     "1544471",
     "1544473",
     "1544475"
    ],
    "spl_id": [
     "ca3e7112-6dfe-403f-af6f-a0051e77d125"
    ],
    "spl_set_id": [
     "efbdafa9-d18c-4e85-b4a2-1e620fc74e50"
    ],
    "package_ndc": [
     "61958-1701-1",
     "61958-1702-1"
    ],
    "nui": [
     "N0000175605",
     "N0000175082",
     "N0000190114"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A Inhibitors [MoA]"
    ],
    "unii": [
     "YG57I8T5M0"
    ]
   },
   "update_date": "04/07/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Zydelig, Tablet, 100 mg (NDC 61958-1701-1)",
   "company_name": "Gilead Sciences, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "04/07/2026",
   "update_type": "New",
   "initial_posting_date": "04/07/2026",
   "package_ndc": "61958-1702-1",
   "generic_name": "Idelalisib Tablet",
   "contact_info": "800-445-3235",
   "related_info": "Discontinuation in the manufacturing of the drug",
   "openfda": {
    "application_number": [
     "NDA205858"
    ],
    "brand_name": [
     "ZYDELIG"
    ],
    "generic_name": [
     "IDELALISIB"
    ],
    "manufacturer_name": [
     "Gilead Sciences, Inc."
    ],
    "product_ndc": [
     "61958-1702",
     "61958-1701"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "IDELALISIB"
    ],
    "rxcui": [
     "1544465",
     "1544471",
     "1544473",
     "1544475"
    ],
    "spl_id": [
     "ca3e7112-6dfe-403f-af6f-a0051e77d125"
    ],
    "spl_set_id": [
     "efbdafa9-d18c-4e85-b4a2-1e620fc74e50"
    ],
    "package_ndc": [
     "61958-1701-1",
     "61958-1702-1"
    ],
    "nui": [
     "N0000175605",
     "N0000175082",
     "N0000190114"
    ],
    "pharm_class_epc": [
     "Kinase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Kinase Inhibitors [MoA]",
     "Cytochrome P450 3A Inhibitors [MoA]"
    ],
    "unii": [
     "YG57I8T5M0"
    ]
   },
   "update_date": "04/07/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Tablet",
   "presentation": "Zydelig, Tablet, 150 mg (NDC 61958-1702-1)",
   "company_name": "Gilead Sciences, Inc.",
   "status": "To Be Discontinued"
  }
 ]
}